



BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS", NO.299, THAMBU CHETTY STREET, CHENNAI – 600001, TAMIL NADU, INDIA
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com
CIN:L24294TN1995PLCO30698

Date: June 29, 2024

To

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001.	National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra East, Mumbai – 400051.
Scrip Code: 532989	Scrip Code: BAFNAPH

Dear Sir/Madam,

Subject: Disclosure under Regulation 30 Of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Temporary Disruption of operations at Manufacturing facility situated at Grantlyon, Chennai

In terms of Regulation 30 read with Schedule III to the Listing Regulations, we hereby inform you that the operations at manufacturing facility of the Company situated at No. 147, Madhavaram Red Hills High Road, Grantlyon, Vadakarai, Chennai-600052 have been temporarily disrupted since June 25, 2024, due to a breakdown of the temperature control equipments.

The Company is taking all necessary steps to resume operations at the facility at the earliest. The delay in communication was due to the time required for a thorough assessment of the rectifications needed and the exploration of alternate options to resume operations by the Company.

The information as required under SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 will be submitted to exchanges once we are able to quantify the impact of the disruption.

We request you to take the information on record.

Thanking You.

For **BAFNA PHARMACEUTICALS LIMITED**

Shanmugam Hemalatha

Whole-Time Director
(DIN: 02714329)